Vemurafenib (Zelboraf) is a BRAF kinase inhibitor that blocks tumor growth by hindering cellular proliferation in melanoma cells with the BRAF mutation (U.S. Food and Drug Administration [FDA], 2011). Here, BRAF is linked to melanoma.